Atrial fibrillation can cause the affected part of the heart to stop pumping blood properly and can bring on serious conditions such as angina and stroke.
The dose-ranging study will measure the safety and efficacy of oral RSD1235 over 28 days of oral dosing in patients at risk of recurrent atrial fibrillation.
The majority of patients enrolled will have experienced atrial fibrillation for greater than 30 days and less than 180 days in duration. The study will enroll 180 patients across 75 centers in Canada, US and Europe.
“We are excited to initiate the next stage of our oral RSD1235 development program.” stated Bob Rieder, president and CEO of Cardiome. “This phase IIa study will provide us with valuable data to help us advance this clinically and commercially exciting program.”